Related Experiment Video
Updated: Aug 7, 2026
10:28
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Drug insight: Clopidogrel nonresponsiveness
Paul A Gurbel1, Udaya S Tantry
1Sinai Center for Thrombosis Research, Baltimore, MD 21215, USA. pgurbel@lifebridgehealth.org
Nature Clinical Practice. Cardiovascular Medicine
|July 1, 2006
Summary
Clopidogrel nonresponsiveness contributes to ischemic events despite dual antiplatelet therapy. Understanding variability in drug absorption, metabolism, and interactions is key to overcoming resistance and improving patient outcomes.
Area of Science:
- Cardiology
- Pharmacology
- Thrombosis
Background:
- Platelet reactivity influences atherothrombosis and ischemic events.
- Dual antiplatelet therapy with clopidogrel and aspirin is standard for acute coronary syndromes and percutaneous coronary intervention.
- Despite benefits, stent thrombosis and other ischemic events persist, partly due to clopidogrel nonresponsiveness.
Purpose of the Study:
- To review clopidogrel response variability and nonresponsiveness.
- To explore mechanisms underlying nonresponsiveness to clopidogrel.
- To discuss strategies for overcoming clopidogrel resistance.
Main Methods:
- Literature review of studies on clopidogrel response and nonresponsiveness.
- Analysis of factors contributing to variability in drug efficacy.
- Synthesis of current research on antiplatelet treatment.
Main Results:
- Nonresponsiveness to clopidogrel is linked to factors like absorption, metabolism, drug interactions, and genetic polymorphisms.
- These factors impact the conversion of clopidogrel to its active metabolite and its antiplatelet effect.
- Existing therapeutic strategies may not fully address clopidogrel resistance in all patients.
Conclusions:
- Clopidogrel nonresponsiveness is a significant clinical issue.
- Addressing variability in drug response is crucial for preventing ischemic events.
- Optimizing antiplatelet therapy may involve dose adjustments or alternative P2Y12 inhibitors.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:21Factors Affecting Drug Response: Overview
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...